Compare Intuit Inc. (INTU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Intuit Inc. trades at $309.12 (market cap $80.56B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Intuit Inc. is far larger — about 16.5× Travere Therapeutics Inc. Common Stock's market cap, and Intuit Inc. pays a 1.83% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 67 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| INTU | TVTX | |
|---|---|---|
Market Cap | $80.56B | $4.88B |
Volume | 3,646,799 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $683.39 | $67.52 |
52-Week Low | $255.07 | $26.79 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $81.78B | $5.01B |
Dividend Yield | 1.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $305.99, up 1.07% with strong earnings momentum after beating Q4 2025 and Q1-Q2 2026 EPS estimates. The stock shows bullish technical signals with support at $302 and resistance at $312. Fundamentally, revenue grew to $18.83B in 2025 with a robust 21.29% net margin, while valuation ratios like P/E of 18.31 appear reasonable. Recent news highlights growth in QuickBooks monetization and AI initiatives, though class action lawsuits create near-term uncertainty.
Outlook remains positive with analyst consensus target of $379.68 (24% upside) and 60% buy ratings. Key opportunities include sustained revenue growth and margin expansion, while risks involve legal overhangs and competitive pressures in financial software. The stock offers attractive fundamentals but requires monitoring of lawsuit developments.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
